Profile data is unavailable for this security.
About the company
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
- Revenue in USD (TTM)54.73m
- Net income in USD-277.34m
- Incorporated2003
- Employees260.00
- LocationMerus NVUppsalalaan 17, 3rd & 4th floorUTRECHT 3584 CTNetherlandsNLD
- Phone+31 850162500
- Websitehttps://merus.nl/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | 58.89m | -240.88m | 3.12bn | 208.00 | -- | 3.68 | -- | 52.99 | -3.10 | -3.10 | 0.761 | 12.07 | 0.0659 | -- | 5.35 | 313,218.10 | -26.97 | -23.82 | -28.82 | -27.88 | -- | -- | -409.07 | -240.35 | -- | -- | 0.0044 | -- | -40.11 | 74.20 | -52.32 | -- | 89.02 | -- |
| MoonLake Immunotherapeutics | 0.00 | -145.21m | 3.15bn | 100.00 | -- | 7.63 | -- | -- | -2.30 | -2.30 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -27.49 | -- | -28.77 | -- | -- | -- | -- | -- | -- | -9,486.42 | 0.1504 | -- | -- | -- | -230.31 | -- | -- | -- |
| Protagonist Therapeutics Inc | 207.80m | 56.19m | 3.29bn | 124.00 | 69.86 | 4.76 | 56.15 | 15.81 | 0.7586 | 0.7586 | 3.29 | 11.13 | 0.303 | -- | 1.27 | 1,649,214.00 | 8.19 | -7.11 | 8.67 | -7.93 | -- | -- | 27.04 | -21.29 | -- | -- | 0.00 | -- | 624.06 | 351.71 | 448.54 | -- | 6.98 | -- |
| Viking Therapeutics Inc | 0.00 | -128.24m | 3.49bn | 45.00 | -- | 4.12 | -- | -- | -1.15 | -1.15 | 0.00 | 7.54 | 0.00 | -- | -- | 0.00 | -13.98 | -22.44 | -14.39 | -23.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -28.02 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 996.28m | 228.88m | 3.51bn | 653.00 | 15.29 | 4.58 | 14.50 | 3.52 | 1.37 | 1.37 | 5.97 | 4.58 | 1.00 | 1.87 | 9.94 | 1,525,701.00 | 23.03 | -13.15 | 33.80 | -16.74 | 92.04 | 94.49 | 22.97 | -16.00 | 2.80 | -- | 0.00 | -- | 31.85 | 23.08 | 469.50 | -- | -14.26 | -- |
| Scholar Rock Holding Corp | 0.00 | -264.16m | 3.55bn | 196.00 | -- | 11.37 | -- | -- | -2.54 | -2.54 | 0.00 | 3.29 | 0.00 | -- | -- | 0.00 | -78.29 | -45.06 | -88.09 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.1374 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Arcellx Inc | 76.81m | -162.42m | 3.80bn | 163.00 | -- | 9.11 | -- | 49.49 | -2.99 | -2.99 | 1.42 | 7.57 | 0.1076 | -- | -- | 471,220.80 | -22.75 | -27.24 | -26.90 | -32.13 | -- | -- | -211.46 | -212.50 | -- | -- | 0.00 | -- | -2.16 | -- | -51.86 | -- | 28.52 | -- |
| Merus NV | 54.73m | -277.34m | 4.06bn | 260.00 | -- | 6.32 | -- | 74.12 | -4.12 | -4.12 | 0.8176 | 8.62 | 0.0891 | -- | 1.50 | 210,507.70 | -45.13 | -32.00 | -52.26 | -38.14 | -- | -- | -506.73 | -325.73 | -- | -- | 0.00 | -- | -17.78 | 3.02 | -38.97 | -- | -6.77 | -- |
| Soleno Therapeutics Inc | 0.00 | -198.23m | 4.11bn | 92.00 | -- | 17.04 | -- | -- | -4.62 | -4.62 | 0.00 | 4.79 | 0.00 | -- | -- | 0.00 | -81.42 | -59.81 | -86.61 | -66.17 | -- | -- | -- | -- | -- | -- | 0.1767 | -- | -- | -- | -351.04 | -- | 59.68 | -- |
| Akero Therapeutics Inc | 0.00 | -269.44m | 4.11bn | 69.00 | -- | 3.79 | -- | -- | -3.75 | -3.75 | 0.00 | 13.60 | 0.00 | -- | -- | 0.00 | -26.06 | -36.86 | -27.01 | -38.94 | -- | -- | -- | -- | -- | -- | 0.0317 | -- | -- | -- | -66.09 | -- | -- | -- |
| Metsera Inc | 0.00 | -265.84m | 4.13bn | 74.00 | -- | 8.15 | -- | -- | -2.87 | -2.87 | 0.00 | 4.82 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0165 | -- | -- | -- | -343.01 | -- | -- | -- |
| Krystal Biotech Inc | 333.45m | 123.96m | 4.28bn | 275.00 | 35.71 | 4.35 | 32.76 | 12.84 | 4.15 | 4.15 | 11.17 | 34.07 | 0.346 | 1.11 | 4.45 | 1,212,535.00 | 12.86 | -4.81 | 13.77 | -5.07 | 93.20 | -- | 37.18 | -41.51 | 9.27 | -- | 0.00 | -- | 473.02 | -- | 715.58 | -- | -7.91 | -- |
| Cytokinetics, Inc. | 19.22m | -615.26m | 4.42bn | 498.00 | -- | -- | -- | 229.99 | -5.31 | -5.31 | 0.1658 | -2.23 | 0.0186 | -- | 13.51 | 38,590.36 | -59.38 | -45.50 | -67.48 | -50.38 | -- | -- | -3,201.47 | -748.37 | -- | -16.68 | 1.68 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
| Vaxcyte Inc | 0.00 | -509.63m | 4.64bn | 414.00 | -- | 1.45 | -- | -- | -3.98 | -3.98 | 0.00 | 24.82 | 0.00 | -- | -- | 0.00 | -18.64 | -26.00 | -19.28 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Alkermes Plc | 1.51bn | 355.65m | 4.99bn | 1.80k | 14.29 | 3.30 | 13.02 | 3.30 | 2.12 | 2.10 | 9.00 | 9.17 | 0.7198 | 1.24 | 4.74 | 840,983.30 | 16.91 | 6.99 | 21.53 | 9.14 | 84.42 | 83.31 | 23.49 | 10.68 | 2.92 | -- | 0.00 | 0.00 | -6.36 | 5.87 | -28.32 | -- | -18.11 | -- |
Data as of Jul 11 2025. Currency figures normalised to Merus NV's reporting currency: US Dollar USD
48.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 5.62m | 8.21% |
| Wellington Management Co. LLPas of 31 Mar 2025 | 4.47m | 6.54% |
| Commodore Capital LPas of 31 Mar 2025 | 4.47m | 6.53% |
| RTW Investments LPas of 31 Mar 2025 | 4.17m | 6.09% |
| Paradigm BioCapital Advisors LPas of 03 Apr 2025 | 3.55m | 5.19% |
| Avoro Capital Advisor LLCas of 31 Mar 2025 | 3.00m | 4.38% |
| Samlyn Capital LLCas of 31 Mar 2025 | 2.38m | 3.48% |
| Franklin Advisers, Inc.as of 31 Mar 2025 | 1.95m | 2.85% |
| Holocene Advisors, LPas of 31 Mar 2025 | 1.87m | 2.74% |
| Polar Capital LLPas of 31 Mar 2025 | 1.71m | 2.49% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
